Phathom Pharmaceuticals Inc
PHAT8.920USD
+4.229+90.19%
收盤 06/06, 16:00（美東）報價延遲15分鐘
621.17M總市值
虧損本益比TTM
關於 Phathom Pharmaceuticals Inc 公司
Phathom Pharmaceuticals, Inc. 是一家生物製藥公司。該公司專注於開發和商業化新型胃腸道 (GI) 疾病治療方法。該公司的候選產品包括 VOQUEZNA、VOQUEZNA TRIPLE PAK 和 VOQUEZNA DUAL PAK。其候選產品 VOQUEZNA 含有沃諾拉贊，這是一種口服小分子鉀競爭性酸阻滯劑 (PCAB)。PCAB 是一種阻斷胃酸分泌的新型藥物。沃諾拉贊在治療糜爛性胃食管反流病 (糜爛性 GERD) 以及與抗生素聯合治療幽門螺桿菌 (H. pylori) 感染方面也表現出臨牀益處。GERD 和 H. pylori 感染是兩種最常見的酸性胃腸道疾病。GERD 是一種因酸性胃內容物反流引起令人困擾的症狀和/或併發症而引發的疾病。幽門螺桿菌是一種細菌病原體。
公司簡介
公司代碼PHAT
公司名稱Phathom Pharmaceuticals Inc
上市日期Oct 25, 2019
成立日期2018
CEOMr. Steven Basta
員工數量427
證券類型Ordinary Share
年結日Oct 25
公司地址100 Campus Drive
城市FLORHAM PARK
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編07932
電話18777428466
網址https://www.phathompharma.com/
公司代碼PHAT
上市日期Oct 25, 2019
成立日期2018
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Azmi Nabulsi
Dr. Azmi Nabulsi
Co-Founder, Chief Operating Officer
Co-Founder, Chief Operating Officer
929.34K
-2.52%
Dr. Asit Parikh, M.D., Ph.D.
Dr. Asit Parikh, M.D., Ph.D.
Independent Director
Independent Director
113.50K
+10.19%
Mr. Frank L. Karbe
Mr. Frank L. Karbe
Independent Director
Independent Director
67.50K
+18.42%
Ms. Molly Henderson, CPA
Ms. Molly Henderson, CPA
Chief Financial and Business Officer
Chief Financial and Business Officer
62.79K
-43.33%
Dr. James N. Topper, M.D., Ph.D.
Dr. James N. Topper, M.D., Ph.D.
Independent Director
Independent Director
46.51K
+29.16%
Mr. Michael F. (Mike) Cola
Mr. Michael F. (Mike) Cola
Independent Chairman of the Board
Independent Chairman of the Board
39.80K
+35.84%
Mr. Mark Stenhouse
Mr. Mark Stenhouse
Independent Director
Independent Director
30.00K
+53.85%
Mr. Theodore R. (Ted) Schroeder
Mr. Theodore R. (Ted) Schroeder
Independent Director
Independent Director
21.00K
--
Ms. Heidi K. Kunz
Ms. Heidi K. Kunz
Independent Director
Independent Director
--
--
Mr. Steven Basta
Mr. Steven Basta
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. Azmi Nabulsi
Dr. Azmi Nabulsi
Co-Founder, Chief Operating Officer
Co-Founder, Chief Operating Officer
929.34K
-2.52%
Dr. Asit Parikh, M.D., Ph.D.
Dr. Asit Parikh, M.D., Ph.D.
Independent Director
Independent Director
113.50K
+10.19%
Mr. Frank L. Karbe
Mr. Frank L. Karbe
Independent Director
Independent Director
67.50K
+18.42%
Ms. Molly Henderson, CPA
Ms. Molly Henderson, CPA
Chief Financial and Business Officer
Chief Financial and Business Officer
62.79K
-43.33%
Dr. James N. Topper, M.D., Ph.D.
Dr. James N. Topper, M.D., Ph.D.
Independent Director
Independent Director
46.51K
+29.16%
Mr. Michael F. (Mike) Cola
Mr. Michael F. (Mike) Cola
Independent Chairman of the Board
Independent Chairman of the Board
39.80K
+35.84%
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 6月6日 週五
更新時間: 6月6日 週五
持股股東
股東類型
持股股東
股東統計
佔比
Frazier Life Sciences Management, L.P.
17.15%
Medicxi Ventures (UK) LLP
10.69%
Abingworth Management Limited
5.01%
Invesco Advisers, Inc.
4.80%
BlackRock Institutional Trust Company, N.A.
4.17%
Other
58.18%
持股股東
股東統計
佔比
Frazier Life Sciences Management, L.P.
17.15%
Medicxi Ventures (UK) LLP
10.69%
Abingworth Management Limited
5.01%
Invesco Advisers, Inc.
4.80%
BlackRock Institutional Trust Company, N.A.
4.17%
Other
58.18%
股東類型
股東統計
佔比
Venture Capital
20.26%
Investment Advisor
18.82%
Private Equity
17.76%
Investment Advisor/Hedge Fund
17.55%
Hedge Fund
8.13%
Individual Investor
4.28%
Research Firm
2.58%
Bank and Trust
0.39%
Pension Fund
0.27%
Other
9.96%
機構持股
更新時間: 3月4日 週二
更新時間: 3月4日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q1
309
70.28M
101.09%
-12.22M
2024Q4
311
70.95M
103.79%
-11.79M
2024Q3
293
76.11M
113.29%
+9.50M
2024Q2
284
61.82M
105.14%
-1.53M
2024Q1
280
58.85M
100.56%
-3.74M
2023Q4
274
57.52M
100.58%
-4.32M
2023Q3
267
60.33M
119.18%
-6.87M
2023Q2
263
58.95M
120.15%
+1.98M
2023Q1
253
46.63M
112.72%
-8.47M
2022Q4
251
44.09M
112.53%
-3.76M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Frazier Life Sciences Management, L.P.
10.11M
14.52%
--
--
Dec 31, 2024
Medicxi Ventures (UK) LLP
7.46M
10.72%
--
--
Dec 31, 2024
Abingworth Management Limited
3.50M
5.02%
--
--
Dec 31, 2024
Invesco Advisers, Inc.
3.37M
4.84%
-146.50K
-4.17%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
3.08M
4.42%
+355.55K
+13.06%
Dec 31, 2024
The Vanguard Group, Inc.
2.77M
3.98%
+83.24K
+3.10%
Dec 31, 2024
Ensign Peak Advisors, Inc.
2.53M
3.63%
-54.33K
-2.10%
Dec 31, 2024
New Enterprise Associates (NEA)
1.96M
2.81%
--
--
Dec 31, 2024
Wasatch Global Investors Inc
1.56M
2.24%
+1.31M
+531.29%
Dec 31, 2024
683 Capital Management LLC
1.02M
1.47%
+15.00K
+1.49%
Dec 31, 2024
查看更多
持股ETF
更新時間: 6月6日 週五
更新時間: 6月6日 週五
機構名稱
佔比
Simplify Propel Opportunities ETF
4.82%
Virtus LifeSci Biotech Products ETF
0.93%
iShares Micro-Cap ETF
0.04%
Invesco Nasdaq Biotechnology ETF
0.03%
ProShares Ultra Nasdaq Biotechnology
0.03%
iShares Biotechnology ETF
0.02%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
Schwab U.S. Small-Cap ETF
0.01%
查看更多
Simplify Propel Opportunities ETF
佔比4.82%
Virtus LifeSci Biotech Products ETF
佔比0.93%
iShares Micro-Cap ETF
佔比0.04%
Invesco Nasdaq Biotechnology ETF
佔比0.03%
ProShares Ultra Nasdaq Biotechnology
佔比0.03%
iShares Biotechnology ETF
佔比0.02%
ProShares UltraPro Russell2000
佔比0.01%
iShares Russell 2000 ETF
佔比0.01%
ProShares Hedge Replication ETF
佔比0.01%
Schwab U.S. Small-Cap ETF
佔比0.01%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
